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■ Abstract Objective To describe
the methodology and to present
the baseline findings of the Atten-
tion-deficit/hyperactivity Disorder
Observational Research in Europe
(ADORE) study, the primary objec-
tive of which is to describe the rela-
tionship between treatment regi-
men prescribed and quality of life
of children with ADHD in actual
practice. Methods In this 2-year
prospective observational study,
data on diagnosis, prescribed treat-
ment and outcomes of ADHD were
collected at seven time points by
paediatricians and child psychia-
trists on 1,573 children recruited in
10 European countries. The data
presented here from the 1,478 pa-
tients included in the analyses de-
scribe the baseline condition, ini-
tial treatment regimen prescribed
and quality of life of families with
children with ADHD. Results Pa-
tients had a mean age of 9.0 years
(SD 2.5) and 84 % were male. Physi-
cians diagnoses were made using
DSM-IV (43 %), ICD-10 (32 %) and
both DSM-IV and ICD-10 (12 %).
Mean age of awareness of a prob-
lem was 5.1 years, suggesting an av-
erage delay of approximately 4
years between awareness and diag-
nosis of ADHD. Baseline ADHD
rating scale scores (physician-
rated) indicated moderate to severe
ADHD. Parent-rated SDQ scores
were in agreement and suggested
significant levels of co-existing
problems. CGI-S, CGAS and CHIP-
CE scores also indicated significant
impairment. Patients were offered
the following treatments after the
initial assessment: pharmacother-
apy (25 %), psychotherapy (19 %),
combination of pharmacotherapy
and psychotherapy (25 %), other
therapy (10 %) and no treatment
(21 %). Conclusion The ADORE
study shows that ADHD is similarly
recognised across 10 European
countries and that the children are
significantly impaired across a
wide range of domains. In this re-
spect, they resemble children de-
scribed in previous ADHD sam-
ples.
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Abbreviations
ADHD Attention-Deficit/Hyperactivity Disor-
der
ADORE Attention-deficit/hyperactivity Disor-
der Observational Research in Europe
ADHD-RS-IV ADHD Rating Scale-IV
CD Conduct Disorder
CHIP-CE Child Health and Illness Profile – Child
Edition
CGAS Children’s Global Assessment Scale
CGI-S Clinical Global Impression-Severity
scale
FSI Family Strain Index
HD Hyperkinetic Disorder
HRQoL Health-Related Quality of Life
ODD Oppositional Defiant Disorder
SDQ Strengths and Difficulties Question-
naire
Introduction
Attention-deficit/hyperactivity disorder (ADHD) is a
common neurobiological disorder in children that is
characterised by the core symptoms of developmentally
inappropriate levels of inattention, hyperactivity and
impulsivity. Diagnosis is made on the basis of observa-
tional data and a detailed clinical history, which is used
to assess whether the patient meets diagnostic criteria.
In Europe, there are varied approaches to the diagnosis
of ADHD, with both the DSM-IV criteria of the Ameri-
can Psychiatric Association [1] and the ICD-10 criteria
for hyperkinetic disorder (HD) of the World Health Or-
ganisation [42] being used. According to the DSM-IV
criteria, symptoms of inattention and/or hyperactivity-
impulsivity must persist for at least 6 months, be present
before the age of 7 years, cause impairment in two or
more settings (e.g. at school and at home), and there
must be clear evidence of clinically important impair-
ment in social, academic or occupational functioning.
The ICD-10 criteria for HD is similar to the DSM-IV
ADHD-combined type requiring symptoms of inatten-
tion, hyperactivity and impulsiveness to all be present,
pervasive and result in functional impairments. Thus,
the ICD-10 criteria select a smaller subgroup of children
with more severe symptoms than those identified by the
DSM-IV criteria [41].
Estimates of the prevalence of ADHD vary depending
on the diagnostic criteria used within a study. However,
there is general agreement that the prevalence of DSM-
IV-defined ADHD is between 5 % and 8 %, and that of
ICD-10-defined HD is around 1.5 % [41]. Although
ADHD is diagnosed in many European countries, the
rates of diagnosis are much lower than those reported in
the United States (US) and it is recognised that, in gen-
eral, ADHD is under-diagnosed and under-treated by
clinicians across Europe.Data from the United Kingdom
(UK) and the Netherlands suggest low rates of referral
and diagnosis, and scepticism of medical professionals
regarding the disorder (see [30]). The full extent to
which ADHD varies across European countries has not
been systematically studied. Whilst there will be many
similarities between children with ADHD across these
countries, it is suspected that the differing funding pat-
terns, traditions and historical development of child and
adolescent mental health services across Europe will re-
sult in large variations in the rate of ADHD diagnosis
and in clinical practice.
ADHD rarely presents as an isolated difficulty, but
frequently co-exists with other conditions such as oppo-
sitional defiant disorder (ODD), conduct disorder (CD),
learning disorders, anxiety, depression, epilepsy, tic dis-
orders and Tourette’s syndrome [4, 29]. The presence of
such co-existing conditions can complicate the diagno-
sis of ADHD and contribute to the severity of the hyper-
active/inattentive/impulsive symptoms [40].ADHD also
often results in significant academic, social and emo-
tional problems both at home and school. Children with
severe ADHD often have low self-esteem, develop emo-
tional and social relationship problems, and frequently
under-achieve at school. Moreover, ADHD is a chronic
disorder that often persists into adolescence and adult-
hood, and is associated with continued impairment
[12].ADHD impacts on the daily lives of not only the af-
fected child, but also their family and society in general.
ADHD has been associated with disturbances in the
family, such as strain in the child-parent relationship,
parental marital dissatisfaction, greater conflict be-
tween parents, and high levels of parental stress. These
difficulties can be further compounded by the economic
stresses associated with parental work disruptions and
medical care costs [2].
The full burden of ADHD in Europe has not been es-
tablished, particularly the impact of the disorder and its
treatment on patient quality of life in actual practice. A
recently reported prospective case-control study con-
ducted in Spain found that untreated children with
newly diagnosed ADHD had a worse quality of life than
healthy children or children with newly diagnosed
asthma [10]. Not surprisingly, the quality of life among
children with ADHD worsened as the severity of ADHD
symptoms increased and with the presence of co-mor-
bid psychiatric disorders [21]. At least one randomised
controlled clinical trial has demonstrated quality of life
improvements upon medication treatment [28].
There is also a lack of information about the impact
of ADHD on families, on healthcare utilisation and its
costs in Europe. Most published studies have been con-
ducted in the US and demonstrate a considerable eco-
nomic burden on patients, families and the healthcare
system [22].
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Since there is such a paucity of information about
how ADHD is diagnosed and treated in the naturalistic
setting, the Attention-Deficit/Hyperactivity Disorder
Observational Research in Europe (ADORE) study was
designed as a 24-month, pan-European, prospective,
non-interventional study to evaluate diagnosis, treat-
ment patterns and health outcomes associated with
ADHD [30]. The primary objective of the study is to de-
scribe the relationship between treatment regimen pre-
scribed and quality of life of children with ADHD in ac-
tual practice, over a 2-year period. The secondary
objectives of the ADORE study are to describe: how
treatment regimens are modified over a 2-year period;
the relationship between diagnosis, actual practice and
ratings of ADHD symptom severity; the relationship be-
tween treatment regimen and the severity of ADHD
symptoms and co-existing problems; and the relation-
ship between treatment regimen prescribed and physi-
cians with different medical specialities. This paper de-
scribes the design of the ADORE study and outlines the
baseline characteristics of the study population.
Methods
■ ADORE study design and population
This ongoing, 2-year, prospective, non-interventional,
observational study is being conducted in 10 European
countries: Austria, Denmark, France, Germany, Iceland,
Italy, the Netherlands, Norway, Switzerland, and the UK.
Patient recruitment commenced in June 2003 and was
completed in December 2004. Each participating coun-
try had a maximum patient recruitment period of 6
months.
The treatment choice for patients enrolled in ADORE
is at the full discretion of the participating physician and
reflects the care patients receive under routine clinical
circumstances.
Physicians participating in the study all have experi-
ence in the treatment of ADHD, hyperactive/inatten-
tive/impulsive symptoms and associated problems.
Across countries, such physicians may come from dif-
ferent medical specialities, including child psychiatrists
and paediatricians. Before the study commenced, the
different types of physicians who diagnose and treat
ADHD in each participating country was defined, and
efforts were made to recruit an equal-sized proportion
of physicians from each of these medical specialities to
participate in the study.There was no minimum number
of patients per investigator.
Patients included in the study were required to be
aged 6–18 years, with hyperactive/inattentive/impulsive
symptoms, but no previous formal diagnosis of ADHD
or HD.Patients with mental retardation,autism or schiz-
ophrenia, and those simultaneously participating in
other studies that included treatment interventions
and/or an investigational drug were excluded from the
study.
The study was approved by local ethics committees
or review boards in each participating country. Patient
informed consent followed country regulations, with all
patients or their parents providing at least verbal in-
formed consent for the provision and collection of data
regarding care and outcomes for the duration of the
study (two years).
■ Data collection
Schedule
All data collection occurred during routine physician
visits. The outpatient visit at which patients were en-
rolled served as the baseline data collection point (T1).
Six subsequent data collection periods were defined
over a 2-year period: the first return to physician be-
tween 1 week and 2 months (T2), and then at 3 months
(T3),6 months (T4),12 months (T5),18 months (T6) and
24 months (T7), with a defined data collection target in-
terval range around these times as shown in Fig. 1. The
first routine visit occurring within each time period
served as the data collection point. The study protocol
did not require data to be collected at every target time
interval for a patient to remain in the study. Thus, if a
routine visit was not scheduled during any specified
time period, data were not collected.
Data sources
Data were collected from physicians and parents, with
whichever parent who brought the child to the visit
completing the parent forms. At each visit, they com-
pleted a 12-page form that took approximately 30 min-
utes to complete. The following broad areas of data were
collected at each visit: patient demographics, function-
ing, clinical status, treatment, tolerability of and compli-
ance with treatment, contacts with police and/or social
services, bullying and/or truancy, health-related quality
of life, and medical resource use. In addition, questions
were asked at the baseline visit about the age of the child
when parents first became aware of hyperactive/impul-
sive/inattentive symptoms,and the age of the child when
treatment was first sought for these symptoms.
■ Study measures
Physician reported measures
The ADHD Rating Scale-IV-Parent version-Investigator
completed (ADHD-RS-IV) was used at every visit to as-
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sess ADHD symptom severity [8]. The ADHD-RS-IV is
derived directly from DSM-IV criteria, was adapted for
all languages of participating countries and was vali-
dated within the ADORE sample [7]. Factor analyses
gave evidence for the two expected subscales of the
ADHD-RS-IV: Inattention and Hyperactivity-Impulsiv-
ity.Each of the 18 items in the scale is scored on a 4-point
scale from 0 = never or rarely (never) to 3 = very often
(severe).
The Children’s Global Assessment Scale (CGAS) [37]
and the Clinical Global Impression-Severity (CGI-S)
scale [16] were used at each data collection point to as-
sess the global health status of patients. For the CGAS, a
score of > 70 is generally accepted to indicate good over-
all functioning and a score of < 60 indicates poor func-
tioning that will generally require intervention (a score
of < 60 was used as the benchmark in the DSM-IV field
trials to define the level below which significant impair-
ment occurs and a clinical diagnosis is appropriate). The
CGI-S is a 7-point scale ranging from 1 = normal, not at
all ill to 7 = very severely ill. A score of 4 indicates mod-
erately ill and a score of 5 indicates markedly ill.
The presence and severity of anxiety, depression, CD,
and ODD symptoms was assessed using a scale based on
the 7-point CGI-S scale and scored in the same way, with
those scoring ≥ 4 (moderately ill) being assessed as hav-
ing a significant problem. Other co-existing problems,
such as Tourette’s syndrome, tics, co-ordination prob-
lems, learning disorders,bipolar disorder,psychosis,ob-
sessive-compulsive disorder, asthma and epilepsy, were
assessed as present, not present or unknown. The pres-
ence of additional health problems, such as sleep prob-
lems, decreased appetite, headache and abdominal
pains was also assessed as: present and significantly in-
terfering with functioning; present but not significantly
interfering with functioning; not present; or unknown.
At each data collection point, physicians also
recorded details of any treatment prescribed for ADHD-
related symptoms, including pharmacotherapy, psy-
chotherapy and any other treatments. The name and
daily dose of the pharmacotherapy prescribed were
recorded. Physicians checked a box to indicate which, if
any, psychotherapy/training was provided (including
psychoeducation/counselling, cognitive behavioural
therapy, family therapy, psychodynamic therapy) and
indicated the number of sessions per month. Other
treatments listed included educational interventions in
school, speech therapy, occupational therapy, relax-
ational techniques, hypnosis, psychomotor/physiother-
apy, EEG biofeedback, herb/homeopathy, diet exclusion
and diet supplements. In addition, resource utilisation
such as primary care physician visits, accident and
emergency visits, and any other diagnostic tests per-
formed were recorded. This information will be used in
future analyses to describe the treatment patterns initi-
ated by different physicians for different levels of ADHD
symptom severity. Local published costs will be applied
to this resource utilisation to estimate the direct costs of
treating patients with ADHD.
Parent reported measures
Parent reported emotional and behavioural problems
and functioning of patients was assessed using the
Strengths and Difficulties Questionnaire (SDQ) [14].
The SDQ was developed from the well-established Rut-
ter scales [36]. The properties of the SDQ have been well
researched in various international studies that gave ev-
idence for the good psychometric properties and facto-
rial consistency of this scale [15, 35]. The SDQ is com-
pleted by parents and consists of 25 items that refer to
different emotions or behaviours of the child, with each
Fig. 1 Data collection schedule for the ADORE study
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item scored as 0 = not true, 1 = somewhat true, or
2 = certainly true. The SDQ reports a total score and 5
subscale scores, with each subscale (emotional symp-
toms, conduct problems, hyperactivity/inattention, peer
relationship problems and prosocial behaviour) consist-
ing of 5 items each. Cut-off scores for the SDQ parent
completed version are (according to the UK norms):
total problems “borderline” 14–16, “abnormal” ≥ 17;
conduct problems “borderline”3,“abnormal”≥ 4; hyper-
activity “borderline”6,“abnormal”≥ 7; emotional symp-
toms “borderline” 4, “abnormal” ≥ 5; peer problems
“borderline” 3,“abnormal” > 4; and prosocial behaviour
“borderline” 5,“abnormal” ≤ 4. The validity and reliabil-
ity of the SDQ parent completed version was confirmed
for the ADORE study population, as reported elsewhere
in this supplement [3].
Health-related quality of life (HRQoL) was assessed
at every data collection point using the parent report
form of the Child Health and Illness Profile-Child Edi-
tion (CHIP-CE) [32, 33]. The CHIP-CE is a reliable and
well-validated instrument that measures overall HRQoL
and, amongst other areas, allows assessment of patient
mental health, self-esteem, general behaviour and in-
volvement with family and peers. It consists of 76 items
covering the five domains of Satisfaction, Comfort, Risk
Avoidance, Resilience and Achievement. The validity
and reliability of the parent report form of the CHIP-CE
in this pan-European sample of children and adoles-
cents with ADHD was confirmed, as reported elsewhere
in this supplement [31]. Raw scores on the CHIP-CE are
converted into standard scores based on a US control
sample, such that a score of 50 is the mean for a healthy
population and each 10 units indicates a change of one
standard deviation from this mean.
The level of strain, stress and other reactions in fam-
ilies of a child with ADHD was also assessed using a brief
6-item questionnaire – the Family Strain Index (FSI) –
developed specifically for the study [34].
■ Analysis
Initial analyses of the ADORE study focus on describing
the characteristics of the patients recruited to the study.
All data are presented as summary descriptive statistics:
means, standard deviations (SD) or percentages, as ap-
propriate.
Results
■ Patient characteristics and diagnosis
Across the 10 participating countries, 244 investigators
enrolled at least one patient. A total of 1,573 patients
were enrolled in the study, with the number of patients
enrolled in each country exceeding the enrolment tar-
get. Of the patients enrolled, 95 (6 %) were excluded
from the analyses for the following reasons:
methylphenidate (MPH) treatment taken prior to study
(n = 61), outside age range (n = 11), enrolled in another
clinical trial (n = 1) and failure to meet other inclu-
sion/exclusion criteria (n = 22).
A total of 1,478 patients were included in the analysis
at baseline; they had a mean age of 9.0 years (SD 2.5) and
the majority of patients were male (84 %). The number
of patients included in the baseline analysis of the
ADORE study by country is summarised in Table 1, to-
gether with the patient demographics (age, gender),
paid employment status of parents, family history of
ADHD, patient age at first awareness of problems and
patient age when treatment was first sought. The major-
Table 1 Sample descriptive data, employment status of parents, family history of ADHD and age of awareness of children’s problems
Country Patients analysed, Mean age, Male, % Mother Father Family history Mean age at first Mean age when first 
N (% of sample) years (SD) working, % working, % of ADHD, % awareness of problems, sought treatment, 
years (SD) years (SD)
Austria 73 (5) 9.3 (2.7) 94 65 97 55 4.5 (2.3) 7.2 (3.1)
Denmark 32 (2) 9.2 (2.1) 91 87 86 62 4.3 (2.4) 5.5 (2.4)
France 241 (16) 8.8 (2.2) 88 NC NC 50 5.2 (2.7) 7.5 (2.7)
Germany 434 (29) 8.7 (2.1) 79 64 94 69 5.0 (2.5) 7.0 (2.3)
Iceland 46 (3) 9.5 (2.4) 79 80 95 76 5.8 (2.4) 7.3 (2.4)
Italy 109 (7) 8.5 (2.4) 86 66 98 58 5.2 (2.5) 7.4 (2.5)
Netherlands 212 (14) 9.1 (2.9) 86 75 97 66 5.1 (3.3) 7.7 (3.2)
Norway 50 (3) 9.8 (2.4) 74 76 89 71 4.5 (2.5) 7.3 (2.5)
Switzerland 57 (4) 9.7 (3.0) 89 65 100 76 5.9 (3.2) 7.9 (2.9)
UK 223 (15) 9.3 (2.7) 86 52 80 64 5.3 (3.0) 7.6 (3.1)
All 1,478 (100) 9.0 (2.5) 84 66 93 64 5.1 (2.7) 7.3 (2.8)
Data are presented as % within country unless indicated otherwise. SD standard deviation, NC data not collected in France
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ity of patients were recruited in the German speaking
countries (Germany, Austria and Switzerland); other
major parts of the sample were from France, UK, the
Netherlands and Italy. Most children lived with both bi-
ological parents (66 %), with most of the others either
living with a single biological parent (17 %) or a biolog-
ical parent and a step parent (11 %) (data not shown). In
the majority of families, at least one parent had paid
work.The figures on employment do not distinguish be-
tween those parents who are unemployed due to eco-
nomic conditions or due to illness of the child and those
who are voluntarily out of work.
For 64 % of cases in all European countries, the infor-
mation was given that at least one relative in the family
of the child had a history of ADHD. However, the major-
ity of mothers (58 %) and fathers (76 %) had no health
problems recorded at baseline. Parental health problems
were predominantly emotional and showed conside-
rable variation between countries and parent gender,
ranging from 7 % in Iceland to 57 % in Italy for mothers,
and from 3 % in Iceland to 30 % in Italy for fathers.There
were only a few guardians (n = 116) in the sample and
the majority (88 %) had no health problems.
For the total study population, the mean age of the
child at first awareness of problems was 5.1 years (SD
2.7) and the mean age when treatment was first sought
was 7.3 years (SD 2.8), giving a delay of just over 2 years
between first becoming aware of the problem and seek-
ing treatment. As the mean age of the child at baseline
when enrolled into the study was 9.0 years (SD 2.5), this
means that it took approximately 4 years across all coun-
tries from first recognition of a behaviour problem to re-
ceiving a diagnosis of ADHD. The pattern was similar
for each country except Denmark, where there was a
younger age of first awareness of problems (mean 4.3
years) and first seeking treatment (mean 5.5 years), al-
though age at enrolment (mean 9.2 years) was similar to
that in other countries.
■ ADHD diagnosis
Across the European countries participating in the
ADORE study (excluding France where clinicians opted
not to answer this question), physicians reported that
they had used formal diagnostic criteria to diagnose
ADHD or HD in 92 % of children in the study.A diagno-
sis of ADHD was made using DSM-IV criteria alone in
43 % of patients and a diagnosis of HD using the ICD-10
criteria alone in 32 % of patients.There were notable dif-
ferences between countries in the use of the DSM-IV
and ICD-10 criteria. In the Netherlands, Italy and the
UK, most cases of ADHD were diagnosed using the
DSM-IV criteria (82 %, 69 % and 57 % respectively),
whereas use of the ICD-10 criteria was preferred in the
other countries. Both DSM-IV and ICD-10 criteria were
used for 12 % of patients, especially for patients in Ice-
land (32 %), Germany (18 %) and Italy (18 %).
Further examination of the criteria used for diagnos-
ing ADHD (DSM-IV alone, ICD-10 alone, both DSM-IV
and ICD-10) revealed no gender differences (data not
shown). Across the participating countries (excluding
France), 91 % of girls and 93 % of boys were given a di-
agnosis of ADHD using diagnostic criteria.
■ Symptom and impairment levels at baseline
For the total study population at baseline, the mean
scores on the physician-rated scales were as follows: to-
tal ADHD-RS-IV score 35.8 (SD 9.2); overall CGI-S score
4.4 (SD 0.9); CGAS score 55.2 (SD 10.6). The mean SDQ
total difficulties score was 20.4 (SD 6.0) and for the SDQ
subscales, the mean scores were: conduct problems 4.5
(SD 2.3), hyperactivity-inattention 8.3 (SD 1.7), emo-
tional symptoms 4.0 (SD 2.4), peer relationships prob-
lems 3.7 (SD 2.5), and prosocial behaviour 6.8 (SD 2.3).
The mean scores for each of the CHIP-CE domains were
considerably reduced compared with healthy popula-
tion norms (mean 50.0, SD 10.0): Satisfaction 32.8 (SD
14.4), Comfort 42.5 (SD 10.6), Resilience 36.0 (SD 12.2),
Risk Avoidance 29.9 (SD 13.6), and Achievement 30.3
(SD 10.6). For each of these rating scales, the scores were
similar between countries (data not shown). Taken to-
gether, these results indicate a medium to high level of
severity of illness among the ADORE study ADHD pa-
tients at baseline.
■ Co-existing problems and somatic complaints
The majority of patients (80 %) had at least one co-ex-
isting problem (excluding asthma and epilepsy, which
were present in 8 % and < 1 % of patients, respectively),
and 51 % of patients had two or more co-existing prob-
lems. The number (%) of patients overall and within
each country with co-existing problems are summarised
in Table 2. The most common co-existing problems were
learning disorders (56 %), CD and/or ODD (41 %), co-
ordination problems (33 %), anxiety and/or depression
(18 %) and tics and/or Tourette’s (8 %), although the
rates of these disorders varied considerably between
countries. Additionally, there were very low rates of co-
existing obsessive compulsive disorder (2 %), bipolar
disorder (< 1 %) or psychosis (< 1 %). More details on
co-existing psychiatric problems in the ADORE sample
at baseline are presented by Steinhausen et al. [39].
Sleep problems that were present and significantly
interfering with patient’s functioning or quality of life
were reported in 14 % of all patients. However, there
were variations between countries, with sleep problems
being present and interfering in less than 1 % of patients
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in Italy up to 20 % of patients in the Netherlands. Other
somatic symptoms were present in a low proportion of
patients at baseline: decreased appetite (1 %), headaches
(5 %) and abdominal pains (4 %).
■ Involvement in bullying
Overall, parents reported to physicians that 38 % of chil-
dren with ADHD were involved in bullying; 15 % as vic-
tims only, 14 % as the bully only and 9 % as a combina-
tion of victim and bully. Italy had the lowest proportion
of patients involved in bullying (22 %) followed by Nor-
way (29 %), Iceland (26 %), UK (33 %), Switzerland
(34 %),Germany (35 %),Denmark (46 %),France (46 %),
the Netherlands (48 %) and Austria (59 %).
■ Treatment prescribed/proposed
Pharmacotherapy was the leading choice of treatment
prescribed/proposed at the baseline visit, being pre-
scribed for 50 % (734/1471) of patients with data avai-
lable. Likewise, psychotherapy was prescribed for 44 %
(655/1472) of patients and 43 % (622/1436) were pre-
scribed “other”therapy at the baseline visit. Looked at in
a different way, 19 % of patients were prescribed psy-
chotherapy ± “other” treatment, 25 % pharmacotherapy
± “other” therapy, 25 % combined psychotherapy and
psychotherapy ± “other” therapy, 10 % “other” therapy
only and 21 % were not prescribed treatment at this
time. There were wide variations between countries in
the types of treatment prescribed at baseline as shown
in Table 3.
Number (%) patients with co-existing problem
Country Anxiety and/ CD and/or ODD Tics/Tourettes Learning Coordination
or Depression Problems Problems
Austria 4 (6) 22 (32) 5 (7) 33 (52) 22 (33)
Denmark 4 (13) 16 (52) 4 (13) 23 (77) 14 (47)
France 105 (44) 130 (54) 25 (11) 148 (63) 62 (27)
Germany 57 (14) 197 (46) 20 (5) 262 (64) 168 (41)
Iceland 9 (20) 16 (34) 12 (26) 20 (44) 15 (33)
Italy 18 (17) 28 (26) 4 (4) 41 (41) 10 (9)
Netherlands 27 (13) 75 (36) 22 (10) 113 (55) 63 (30)
Norway 7 (15) 18 (37) 7 (15) 17 (46) 18 (41)
Switzerland 8 (15) 9 (16) 2 (4) 21 (42) 20 (38)
UK 16 (8) 91 (41) 21 (9) 84 (44) 74 (34)
All 255 (18) 602 (41) 122 (8) 762 (56) 466 (33)
Data are presented as number and % of patients within each country. CD Conduct Disorder, ODD Oppositional
Defiant Disorder
Table 2 Co-existing problems identified by physi-
cian at baseline
Table 3 Treatment prescribed or proposed at baseline visit, by country
% Patients within each country
Country Psychotherapy Combined psychotherapy, Pharmacotherapy Other therapy only None
± other therapy pharmacotherapy ± other therapy ± other therapy
Austria (N = 67) 52 9 6 16 16
Denmark (N = 32) 19 3 38 22 19
France (N = 234) 27 36 23 5 9
Germany (N = 416) 19 23 21 10 27
Iceland (N = 45) 11 31 20 0 38
Italy (N = 105) 30 9 10 22 30
Netherlands (N = 206) 4 46 40 3 7
Norway (N = 49) 14 14 12 16 43
Switzerland (N = 53) 23 38 17 8 15
UK (N = 221) 11 11 38 17 23
All (N = 1,428, 100 %) 19 (n = 270) 25 (n = 356) 25 (n = 360) 10 (n = 148) 21 (n = 294)
Data missing for 50 patients
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Discussion
The ADORE study is not intended to provide a sophisti-
cated comparison of the diagnosis and treatment pat-
terns or epidemiological phenomena of ADHD in the
participating European countries. Rather, its primary
aim is to describe the real world population of children
with newly diagnosed ADHD in Europe. Because of the
heterogeneity of the sampling method, sample size,
types of investigator and other uncontrolled variables,
the data are not representative for each country and,
therefore, do not allow for conclusive analysis of the dif-
ferences between countries.
The baseline data are intended to describe the char-
acteristics of the sample and serve as a reference from
which the impact of treatment on the child’s condition
and well-being and that of their family can be judged as
the study progresses. The data show the ADORE study
population was young (mean age 9 years) and predomi-
nantly male (84 %), consistent with previous large-scale
studies of ADHD in children, such as the Multimodal
Treatment study of children with ADHD [26]. The ma-
jority of children lived with their parents, both of whom
were working in most cases. The lowest rate of mothers
in paid employment was in the UK (52 %).
Although a formal diagnosis of ADHD or HD was not
required, the majority of children enrolled into the
study were given one of these diagnoses. Interestingly,
although the ICD-10 is the standard instrument of clas-
sification for mental disorders in most European coun-
tries, the majority of investigators in the ADORE study
used the DSM-IV criteria (developed and used in the
US),either alone or together with the ICD-10 criteria, for
diagnosing ADHD. This may be because these physi-
cians are aware that the ICD-10 criteria selects a smaller
group of children with all three symptoms of inatten-
tion, hyperactivity and impulsiveness, and does not dis-
tinguish the three subtypes of ADHD identified by the
DSM-IV criteria (predominantly inattentive, predomi-
nantly hyperactive-impulsive, combined).
The time gap between first recognition of problems
and assessment/diagnosis is striking. We observed ap-
proximately a 2-year difference between the age at first
awareness of symptoms and the age at which treatment
was first sought, and a further 2-year gap between age at
which treatment was first sought and age at final diag-
nosis of ADHD. Importantly, this delay of approximately
4 years until ADHD diagnosis was seen in all participat-
ing countries,although awareness of problems and seek-
ing treatment seemed to occur at a younger age in Den-
mark. This may be due to a higher awareness of ADHD
in Denmark or could be an artefact caused by the low
number of patients from this country participating in
the study. There may be many reasons for the delay be-
tween first awareness of a problem and final diagnosis
of ADHD, including delays in the referral process and in
processing referrals once they are made and a shortage
of available well-trained staff to make the full assess-
ment. Nevertheless, further research on the awareness-
diagnosis-treatment gap would be of considerable value
as earlier diagnosis and treatment intervention may re-
duce the severity and burden of the disorder during the
critical stage of a child’s development.
One of the strengths of this study is its ability to de-
scribe the levels of impairment across a wide range of
well-validated measures in a group of children who are
treatment naïve with respect to their ADHD symptoms
and who have been referred to child and adolescent psy-
chiatric and paediatric services across Europe. At base-
line, this group of children was found to have moderate
to severe symptoms of ADHD and levels of impairment,
together with significant levels of co-existing problems
as assessed by both physicians (ADHD-RS-IV,CGI-S and
CGAS) and parents (SDQ). The mean ADHD-RS-IV
score (35.8) whilst relatively high is somewhat lower than
that seen in recent clinical trials of ADHD medication,
where scores were in the range of 37 to 41 [24, 25]. The
mean CGI-S score (4.4) suggests that most patients were
rated as moderately or severely ill and the mean CGAS
score (55.2) fell well below the cut-off for significant clin-
ical impairment. The mean SDQ total difficulties score
and subscale scores for conduct problems and hyperac-
tivity-inattention were all within the abnormal range,
those for emotional symptoms and peer problems were
borderline, with only prosocial behaviour falling within
the normal range. These clinical indicators of severity
were accompanied by significantly impaired measures of
quality of life assessed using CHIP-CE, which averaged
two standard deviations below the expected scores for a
healthy population. Recent studies measuring HRQoL
with the Child Health Questionnaire found that ADHD
impairs many aspects of a child’s life; HRQoL was closely
associated with clinical symptoms and became poorer as
ADHD symptom severity increased [21, 23]. Taken to-
gether, these findings reinforce previous findings on the
impact of ADHD and suggest that those children being
referred to clinical services across Europe are indeed in
need of treatment and support.
ADHD not only affects the child, but also has a sig-
nificant impact on family functioning [18], although it is
not clear how this varies among countries. In the
ADORE study, the burden of ADHD on the family was
reflected in the health problems experienced by parents,
especially emotional problems, which affected up to half
of mothers and up to one-quarter of fathers, depending
on the country.An important consideration in the effec-
tive treatment of ADHD is how its affects the health and
functioning of the entire family. Family stress and strain
at baseline, assessed using the FSI, is reported elsewhere
in this issue, together with an assessment of the reliabil-
ity and factor structure of the questionnaire [34]. Al-
though the FSI has not previously been standardised, it
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is anticipated that the scores obtained in the ADORE
study will allow us to track the impact of treatment on
family strain as the study progresses.
Consistent with previous findings [4], the majority of
children in the ADORE study had one or more co-exist-
ing problems in addition to their clinically impairing
ADHD symptoms. Learning disorders and behavioural
problems, such as ODD and CD, were the most common
co-existing problems in the ADORE study population, in
agreement with previous reports in school-aged chil-
dren with ADHD [4, 5, 13, 17]. Co-ordination problems
and emotional problems were also relatively common
and occurred in this sample at similar rates to those re-
ported in previous samples [4, 5, 13, 17].
Sleep disturbances are common in children with
ADHD and have a reported prevalence of up to 50 % [6].
Although 40 % of children in the ADORE study were re-
ported to have sleep problems, only 14 % of children had
sleep problems that were felt by their parents to signifi-
cantly interfere with their functioning and quality of
life. Interestingly, the rate of sleep problems varied be-
tween countries and was very low (< 1 %) in Italy.The re-
lationship between sleep and ADHD is complex and not
well understood [19, 20, 27]. Sleep disturbance is an im-
portant symptom in unmedicated children with ADHD,
but is also considered a frequent side effect of stimulant
treatment [38].
Involvement in bullying also appears to be a consid-
erable problem for children with ADHD in all the par-
ticipating countries, confirming the widespread social
problems faced by this group of children.
The baseline data from the ADORE study indicated
that there may be differences between European coun-
tries in their approach to early ADHD treatment. Doc-
tors in the Netherlands, UK and Denmark favoured the
early initiation of pharmacotherapy alone, whereas
those in Austria and Italy primarily used psychotherapy
at this stage. Combination therapy was the initial treat-
ment option for many clinicians in the Netherlands,
Switzerland, France, Iceland and Germany. There may
be many reasons for these differences. For example, spe-
cial legislation in Italy does not allow the use of
methylphenidate beyond some privileged institutions,
which undoubtedly influences the prescribing habits of
Italian physicians. In other countries, the limited avai-
lability of trained staff to provide psychological inter-
ventions (particularly within a paediatric setting)
prompts the early use of medication. It is also important
to recognise that for many but not all of the ADORE sub-
jects, these initial data will have been gathered at the
time of initial diagnosis and that many clinicians will re-
frain from prescribing stimulant medication at this first
appointment feeling that either a further period of as-
sessment or psychoeducation/counselling is required
first. Indeed, the European guidelines for hyperkinetic
disorders [41] suggest that a full assessment should in-
volve more than one meeting with the child and family.
Moreover, following diagnosis, medication should be
initiated early for cases of severe pervasive disabling
ADHD, but that an initial trial of psychological therapy
is appropriate for those with less severe ADHD, with
medication being reserved for those who do not respond
to this treatment. The different pathways through treat-
ment taken by the ADORE study subjects will become
clearer with the longitudinal data over 2 years and will
be the subject of future reports.
■ Limitations
There are certain limitations associated with observa-
tional studies. The non-randomised enrolment proce-
dure and limited selection criteria increases the like-
lihood of treatment group bias and within- and
between-group heterogeneity. Furthermore the assess-
ments in the ADORE study are based on investigator and
parental reports, and no information was collected from
the child or their teachers. Although parental reports
have previously been shown to be reliable [9, 11], the un-
blinded nature of the study means that post-baseline
ratings by investigators and parents may be influenced
by bias about treatment. Also, although all of the inves-
tigators involved in the study attended an initial train-
ing session, the large number of recruiting sites and
raters did not allow for an assessment of inter-rater reli-
ability to be made.
Conclusion
The baseline findings of the ADORE study indicate that
ADHD is a disorder that is recognised and diagnosed by
clinicians in Europe, and that those children diagnosed
by these clinicians suffer from high symptom levels, sig-
nificant impairment and poor quality of life. In this re-
spect, they bear close resemblance to children included
in previous ADHD research studies. There was a broad
agreement between physicians and parents in the 10 Eu-
ropean countries on ADHD symptom severity, co-exist-
ing problems, burden of illness and quality of life, al-
though there appear to be some differences between
countries in the use of ADHD diagnostic criteria and
initial treatment interventions. The longitudinal data
provided by the ADORE study will determine whether
these similarities and differences are sustained over the
2-year study period.
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